Adage Capital Partners
ELVN icon

Adage Capital Partners’s Enliven Therapeutics ELVN Stock Holding History

Adage Capital Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-73,000
Closed -$1.49M – 941
2025
Q3 		$1.49M Sell
73,000
-23,000
-24% -$464K ﹤0.01% 823
2025
Q2 		$1.93M Sell
96,000
-354,000
-79% -$6.7M ﹤0.01% 762
2025
Q1 		$8.86M Sell
450,000
-200,000
-31% -$4.3M 0.02% 610
2024
Q4 		$14.6M Sell
650,000
-150,000
-19% -$3.89M 0.03% 512
2024
Q3 		$20.4M Sell
800,000
-40,000
-5% -$926K 0.04% 443
2024
Q2 		$19.6M Buy
+840,000
New +$17.7M 0.04% 441

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners's ELVN Position: Q4 2025 in Review

Adage Capital Partners sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 73,000 shares — an estimated $1.49M sold.

Adage Capital Partners first reported a position in ELVN in Q2 2024 and held it in 6 quarters. The position peaked at $20.4M in Q3 2024. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Adage Capital Partners reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 73,000 Enliven Therapeutics shares in Q4 2025, an estimated $1.49M.
  • Adage Capital Partners first reported a position in Enliven Therapeutics in Q2 2024 and held it in 6 quarters.
  • Adage Capital Partners's Enliven Therapeutics position peaked at $20.4M in Q3 2024.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.